GlassScriptPhysician profile
Ankmalika A Gupta
NPI 1790946440
$175,900.62
in general payments reported to CMS, 2019-2025
22 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $30K · 2021: $28K · 2022: $20K · 2023: $1,171 · 2024: $143 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,960 · Food and Beverage: $782 · Consulting Fee: $32.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,960.00 |
| Food and Beverage | $782.43 |
| Consulting Fee | $32.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41,203.14 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $34,507.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $26,276.89 | 2019-2022 | |
| Shire North American Group INC | $23,329.70 | 2019 | |
| Pfizer INC. | $18,964.59 | 2019-2025 | |
| Csl Behring | $15,896.33 | 2019-2022 | |
| Genzyme Corporation | $8,023.93 | 2019-2025 | |
| Dermira, INC. | $5,246.07 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $1,125.00 | 2020 | |
| Grifols USA, LLC | $297.00 | 2022-2025 | Xembify |
| Glaxosmithkline, LLC. | $219.09 | 2020-2025 | Nucala |
| Bio Products Laboratory USA, INC. | $200.21 | 2019 | |
| Arcutis Biotherapeutics, INC. | $171.31 | 2025 | Zoryve |
| Lilly USA, LLC | $120.06 | 2025 | Ebglyss |
| Incyte Corporation | $102.31 | 2022-2024 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $85.80 | 2019-2025 | Ruconest |
| Optinose US, INC. | $37.74 | 2022-2024 | |
| Adma Biomanufacturing LLC | $32.09 | 2024-2025 | |
| Octapharma USA, INC. | $17.20 | 2024 | Octagam Immune Globulin (Human) |
| Therapeuticsmd, INC. | $16.85 | 2020 | |
| Abbott Laboratories | $14.50 | 2019 | |
| Jubilant Hollisterstier LLC | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankmalika Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.